SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-469125"
 

Search: onr:"swepub:oai:DiVA.org:uu-469125" > [F-18]THK5317 imagi...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

[F-18]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease

Chiotis, Konstantinos (author)
Karolinska Institutet
Savitcheva, Irina (author)
Karolinska Univ Hosp, Med Radiat Phys & Nucl Med, Stockholm, Sweden.
Poulakis, Konstantinos (author)
Karolinska Institutet
show more...
Saint-Aubert, Laure (author)
Karolinska Inst, Dept Neurobiol Care Sci & Soc, Nordberg Translat Mol Imaging Lab, Div Clin Geriatr,Ctr Alzheimer Res, Stockholm, Sweden.;Univ Toulouse, Toulouse NeuroImaging Ctr, INSERM, UPS, Toulouse, France.
Wall, Anders (author)
Uppsala universitet,Radiologi
Antoni, Gunnar (author)
Uppsala universitet,Preparativ läkemedelskemi
Nordberg, Agneta (author)
Karolinska Institutet
show less...
Karolinska Institutet Karolinska Univ Hosp, Med Radiat Phys & Nucl Med, Stockholm, Sweden (creator_code:org_t)
2020-07-03
2021
English.
In: Molecular Psychiatry. - : Springer Nature. - 1359-4184 .- 1476-5578. ; 26:10, s. 5875-5887
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Cross-sectional studies have indicated potential for positron emission tomography (PET) in imaging tau pathology in Alzheimer's disease (AD); however, its prognostic utility remains unproven. In a longitudinal, multi-modal, prognostic study of cognitive decline, 20 patients with a clinical biomarker-based diagnosis in the AD spectrum (mild cognitive impairment or dementia and a positive amyloid-beta PET scan) were recruited from the Cognitive Clinic at Karolinska University Hospital. The participants underwent baseline neuropsychological assessment, PET imaging with [F-18]THK5317, [C-11]PIB and [F-18]FDG, magnetic resonance imaging, and in a subgroup cerebrospinal fluid (CSF) sampling, with clinical follow-up after a median 48 months (interquartile range = 32:56). In total, 11 patients declined cognitively over time, while 9 remained cognitively stable. The accuracy of baseline [F-18]THK5317 binding in temporal areas was excellent at predicting future cognitive decline (area under the receiver operating curve 0.84-1.00) and the biomarker levels were strongly associated with the rate of cognitive decline (beta estimate -33.67 to -31.02,p < 0.05). The predictive accuracy of the other baseline biomarkers was poor (area under the receiver operating curve 0.58-0.77) and their levels were not associated with the rate of cognitive decline (beta estimate -4.64 to 15.78,p > 0.05). Baseline [F-18]THK5317 binding and CSF tau levels were more strongly associated with the MMSE score at follow-up than at baseline (p < 0.05). These findings support a temporal dissociation between tau deposition and cognitive impairment, and suggest that [F-18]THK5317 predicts future cognitive decline better than other biomarkers. The use of imaging markers for tau pathology could prove useful for clinical prognostic assessment and screening before inclusion in relevant clinical trials.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view